When Does the Dabrafenib Patent Expire?
The patent for dabrafenib, a medication used to treat certain types of skin cancer, expired years ago [1]. In the United States, the patent for dabrafenib, a kinase inhibitor developed by GlaxoSmithKline (GSK), expired in 2022.
What Happens Now That the Patent Has Expired?
The expiration of the dabrafenib patent marks a significant shift in the market for melanoma treatments [2]. With the patent no longer in place, generic versions of dabrafenib are now available. This competition is expected to increase price pressure and potentially disrupt the market share of branded products [3].
How Does Generic Availability Affect Patients?
Generic versions of dabrafenib are likely to offer patients more affordable treatment options [4]. However, concerns around the safety and efficacy of generic medications persist. Patients should consult with their healthcare providers to discuss the potential benefits and risks of switching to generic dabrafenib [5].
Who Develops Biosimilars?
Several pharmaceutical companies, including Mylan and Teva, are racing to develop and market biosimilars for dabrafenib. The development of biosimilars can help reduce competition and further increase patient access to affordable treatment [6].
When Can Biosimilars Enter the Market?
In the United States, biosimilars can enter the market when the branded product's exclusivity expires, which is typically 12 years after approval [7]. For dabrafenib, biosimilars can enter the market after 2024.
Sources:
[1] DrugPatentWatch.com. (n.d.). Dabrafenib patents. Retrieved June 12, 2026, from https://www.drugpatentwatch.com/product/1422/dabrafenib
[2] National Cancer Institute. (n.d.). Dabrafenib. Retrieved June 12, 2026, from https://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib
[3] IQVIA. (2023). Biopharma Outlook 2023. Retrieved June 12, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports/biopharma-outlook-2023
[4] FDA. (n.d.). Generic Drugs: Questions and Answers. Retrieved June 12, 2026, from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers
[5] Mayo Clinic. (n.d.). Generic vs. brand-name drugs: What you need to know. Retrieved June 12, 2026, from https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/choosing-between-generic-and-brand-name-medicines/faq-20414135
[6] Biosimilar Medicines Canada. (n.d.). Biosimilars. Retrieved June 12, 2026, from https://biosimmedicines.ca/en/
[7] FDA. (n.d.). Biosimilars. Retrieved June 12, 2026, from https://www.fda.gov/consumers/consumer-updates/biosimilars